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| INTRODUC TI ON
Current dogma in transplantation uses powerful immunosuppressants to deplete the recipient's immune system and facilitate allograft survival. While effective, the ultimate goal in transplantation may not be in systemic recipient immunosuppression but rather in localized allograft immunomodulation. As early as the 1930s, the potential for ex vivo organ perfusion was realized.
1 Currently, ex vivo perfusion is used in kidney, lung, liver, and heart transplantation. 2, 3 The ex vivo period between transplant procurement and recipient transplantation provides a unique opportunity for transplant engineering without concern for systemic off-target effects. During this period, appropriately targeted pharmacologic and cell-based therapies could be used to engineer immunomodulated transplants while leaving the recipient's immune system entirely intact.
Transplantation inherently requires severing of the donor vasculature during allograft procurement, followed by arterial and venous anastomosis on transplantation. This allows direct access to the allograft circulatory system through at least 1 major artery and vein for pharmacologic or cell-based tissue engineering. Prior work has demonstrated that transplants can be engineered ex vivo via arterial cannulation and seeding with stem cells. 4 This has resulted in reliable stem cell engraftment, differentiation, and establishment of potential regenerative niches in transplanted tissues. Importantly, ex vivo access to allograft circulation provides an opportunity to target therapeutics directly to the allograft endothelium, the critical barrier responsible for mitigating rejection.
Mesenchymal stem cells (MSCs) have emerged as a cell-based therapy in transplantation and may offer one of the most promising avenues for allograft immunomodulation. Bone marrowderived MSCs (BMSCs) have the potential to differentiate into bone, cartilage, and fat. 5 Aside from their progenitor functions, BMSCs possess potent immunomodulatory properties 5 and have been used in human trials of hematopoietic stem cell transfer, 6 treatment of graft-versus-host disease, 7 and solid organ transplantation 8, 9 and are currently being investigated in more than 600 clinical trials (ClinicalTrials.gov). MSCs are thought to exert their immunomodulatory effects through paracrine mechanisms, and the most promising candidates in the MSC secretome include indoleamine 2,3-dioxygenase (IDO), inducible nitric oxide synthase (iNOS), transforming growth factor (TGF)β, and prostaglandins.
10
MSCs are also unique in that they are immune privileged, expressing little MHC I and no MHC II. 11 The potential for BMSCs in transplant engineering has previously been recognized.
12
Currently, transplantation tolerization protocols revolve around regimens aimed to induce mixed donor chimerism through pretransplantation myeloablation and subsequent bone marrow reconstitution with whole bone marrow or hematopoietic stem cell transfer, followed by MSC therapy. [13] [14] [15] [16] [17] [18] [19] [20] 
| MATERIAL S AND ME THODS

| MSC harvest, culture, and priming
BMSCs were harvested from 6-to 8-week-old Lewis rats (recipient) by flushing the femur, tibia, and humerus with Mesencult F I G U R E 1 Ex vivo allograft engineering and in vivo experimental design. Recipient (syngeneic) bone marrow-derived mesenchymal stem cell (BMSCs) are harvested before transplantation and expanded in tissue culture. After allograft procurement, the donor allograft artery is cannulated and recipient BMSCs are perfused directly into the transplant circulation to engineer an immunomodulated allograft. After ex vivo stem cell delivery and engineering of the allograft, the immunomodulated allograft is transplanted into the recipient with low immunogenicity basal media (Stem Cell Technologies, Vancouver, Canada) and passing the resulting cell suspension through a 70-μm filter 
| CD4
+ T cell proliferation assay CD4 + T cell proliferation was measured in response to allogeneic EC activation by using a 3 H-thymidine-based assay. Recipient Lewis rat splenocytes were harvested on the day of experimentation, morcelated into a single cell suspension, and positively selected using CD4 + MACS beads and an LS magnetic column (Miltenyi; Bergisch, Gladbach, Germany). BMSC:EC cocultures were plated into 96-well plates and CD4 + T cells were added. T cell proliferation was assessed by pulsing wells with 3 H-thymidine, and measuring counts per minute.
| Migration assay
BMSC cellular migration in response to an SDF1α (Sigma Aldrich, St. Louis, MO) gradient was measured using a transwell system.
BMSCs in complete Mesencult media were seeded onto the top of the transwell insert, and SDF1α was added to the lower chamber.
After 6 hours, nonmigrating cells from the top of the transwell system were quantified.
| Cell proliferation assay
MSC cellular proliferation was measured by using an MTT Cell Proliferation Assay Kit (Invitrogen, Waltham, MA) in response to cytokine and hypoxia priming at days 0, 3, 7, 10, and 14 after the addition of priming stimulus.
| Rat hindlimb allotransplantation procedure and ex vivo allograft engineering
All experiments were conducted in accordance with the NYU Langone Medical Center Institutional Animal Care and Use Committee guidelines. Anesthesia was induced using 2% isoflurane.
Donor Brown Norway rats were shaved, and an osteomyocutaneous flap was dissected and harvested as previously described. similarly prepped, and the femoral vessels were dissected. The allograft was transplanted by using a polyimide cuff for venous anastomosis and 10-0 nylon suture for the arterial anastomosis. 24 The allograft was inset into the recipient groin area, and skin was closed using 3-0 silk sutures. Cyclosporine (Sigma Aldrich) was administered at a dose of 16 mg/kg for 5 days postoperatively and then withdrawn entirely. Allografts were monitored daily for clinical signs of rejection, which was confirmed histologically. 25 Twenty-five animals were used in total (n = 2 for the unprimed BMSC group, n = 3 syngeneic transplants, and n = 4 for all other treatment groups). 
| BMSC DiI staining and frozen section immunohistochemistry
| Laser Doppler perfusion monitoring of allografts
Allografts were imaged with the use of laser Doppler (Moor LDI, Wilmington, DE) on postoperative day 1 to assess perfusion.
| Nonengineered Brown Norway skin grafts to assess recipient immunocompetence
For select hypoxia-primed BMSC transplants (n = 3), nonengineered
Brown Norway skin grafts were applied between postoperative days 25 and 30 to the contralateral limb of recipient Lewis rats to assess systemic immunocompetence as previously described. 26 Skin grafts were monitored daily for clinical signs of acute rejection, which was confirmed histologically. 
| Data collection and statistical analysis
Pairwise data were compared by using the Student t test. Survival data were compared by using logrank analysis. All statistical analysis was performed using GraphPad Prism software (La Jolla, CA). P < .05
were considered to be statistically significant.
| RE SULTS
| BMSCs mitigate IRI and prevent alloreactivity
Recipient BMSCs displayed characteristic markers (CD90 
| Inflammatory and hypoxic microenvironments prime MSC immunomodulatory functions
Because it is established that BMSCs must be activated to an immunomodulatory phenotype, Cytokine priming also affected the chemotaxis of BMSCs toward a stromal cell-derived factor 1α (SDF1α) gradient, a known mediator of stem cell chemotaxis and recruitment. 22 TNFα-primed
and IFNγ-primed BMSCs demonstrated 30-fold and 17-fold increases in migration, respectively (P < .05 for both compared with unprimed BMSCs) ( Figure 3E ). However, TNFα and IFNγ priming was associated with a 40% to 60% decrease in BMSC cell number by 14 days after IRI compared with nonprimed controls ( Figure 3F ). 
| D ISCUSS I ON
Since its inception, transplantation has relied on postoperative suppression of the recipient's immune system to prevent allograft rejection. However, current pharmacologic immunosuppression regimens predispose patients to significant morbidity and mortality.
Prevention of allograft rejection while maintaining recipient immunocompetence represents the ultimate goal in transplantation. Our work here represents a promising solution to this difficult endeavor. Previous work has demonstrated the potent immunomodulatory properties of MSCs. 5 Here, we used bone marrow-derived
MSCs to provide localized immunomodulation within the allograft.
We used an in vitro coculture system of BMSCs and ECs to approximate our ex vivo transplant environment. In this coculture system, BMSCs ameliorated damage caused by IRI by altering EC expression of genes involved in vascular damage and endothelial injury. This was directly associated with the phenotypic outcomes of reduced endothelial cytotoxicity and reduced alloantigen T cell education, which we correlated to increased IDO expression. In fact, when IDO activity was abolished by a competitive inhibitor, these phenotypic changes were abrogated.
Because BMSCs also display progenitor functions, they must be activated toward an immunomodulatory phenotype. 5 Demonstrative of this principle, there was no difference in the onset of rejection between allografts treated with unprimed BMSCs and control media.
Therefore, we attempted to prime BMSCs to an immunomodulatory fate and maximize their immunosuppressive potential. Known 
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